--- title: 'Spontaneous Application at Aqemia' canonical: 'https://feeny.ai/job/spontaneous-application-aqemia-paris-g6v2bjhsy8v4' type: 'job' last_seen: '2026-09-10' --- # Spontaneous Application at Aqemia - **Company:** Aqemia - **Location:** Paris, France - **Employment:** contract - **Work type:** hybrid - **Posted:** 2022-12-23 - **Last confirmed live:** 2026-09-10 - **Apply:** https://jobs.lever.co/aqemia.com/f2587196-403d-41b3-87d5-b26ab217c8d2 ## Job description Spontaneous Application If you don’t see an open position that fits you, but are still interested in joining the team, please use this form. ## About Aqemia ## Company Overview - **One-liner**: Aqemia is a Paris-based drug discovery company combining generative AI and deep physics to invent novel medicines for difficult-to-treat diseases. - **Entity Type**: Private (venture-backed, post-Series A) - **Headquarters**: Paris, France (with a London, UK office at 29-31 Euston Road) - **Founded**: 2019 - **Founders**: Maximilien Levesque (CEO, physicist, former professor at École Normale Supérieure/CNRS) and Emmanuelle Martiano-Rolland (COO, former Principal at Boston Consulting Group) ## Core Business - **Primary Industry**: Biotechnology Research / AI-driven drug discovery - **Target Customers**: B2B — large pharmaceutical and biotech companies via partnerships, plus wholly owned proprietary drug programs - **Mission**: To invent new medicines — never me-toos — tackling major diseases such as oncology, using physics-based generative AI to discover drug candidates beyond the reach of traditional R&D, without dependence on experimental data. ## Products & Services - **QEMI Platform**: A proprietary drug discovery engine fusing fast, atomic-scale physics with state-of-the-art generative AI to predict drug-target affinities and design novel molecules rapidly and accurately. The platform removes the need for experimental training data, enabling frugal, scalable discovery. - **Wholly Owned Drug Pipeline**: A portfolio of proprietary programs demonstrating superior efficacy and non-toxicity in vivo, with lead programs progressing through optimization. - **Partnered Programs**: Collaborations with leading pharmaceutical and biotech companies, alongside plans to spin out drug candidates into biotech spin-offs for clinical trials. - **Moonshot Programs**: Indication-first initiatives targeting single diseases with high unmet medical need, running multiple shots on goal across different targets. ## Market Standing - **Valuation**: Not disclosed - **Annual Revenue**: USD 7.1M (latest available estimate) - **Total Funding**: USD 119.7M across 8 rounds, including: - Pre-Seed (2019): USD 1.2M led by Elaia - Series A (May 2021): USD 10.8M led by Eurazeo - Series A (Jan 2021): USD 10.2M - Series A (Oct 2022): USD 19.5M led by Bpifrance - Grant (May 2025): USD 7.4M from France 2030 - **Notable Investors/Partners**: Eurazeo, Bpifrance, Elaia, France 2030; collaborations with top pharmaceutical companies - **Growth Signals**: Headcount of 76 employees (+13.2% YoY); workforce distributed across France (63%), UK (24%), and Switzerland (1%); part of the French Tech 120 program; 22,927 LinkedIn followers (+38.6% yearly); 11 active job postings with +37.5% monthly growth ## Competitive Advantages - **Deep Physics Foundation**: Built on 12+ years of academic research in theoretical physics at CNRS, École Normale Supérieure, and the Universities of Oxford and Cambridge; recognized by the American Institute of Physics with 40+ peer-reviewed publications. - **No Experimental Data Dependence**: Unlike conventional AI drug discovery, Aqemia's algorithms do not require experimental training data, enabling faster, cheaper, and more innovative molecule discovery. - **Scalable Engine**: The QEMI platform allows the company to pursue dozens of drug candidates simultaneously, including "moonshot" programs targeting high-unmet-need diseases. - **Frugal, Efficient Discovery**: Physics-first approach scales drug discovery cost-effectively, making it attractive for both proprietary and partnered programs. ## Strategic Focus - Scaling the pipeline to dozens of wholly or partly owned drug candidates and placing them into a constellation of biotech spin-offs for clinical trials. - Balancing broad exploration across multiple targets with indication-first "moonshot" programs in high unmet need areas. - Expanding collaborations with top pharmaceutical companies while growing proprietary programs. - Continuing to recruit exceptional talent across life sciences, AI, software engineering, computational chemistry, and drug discovery in Paris and London. ## Why Work Here - **Culture**: Mission-driven, strongly collaborative international team at the crossroads of technology and life sciences; values collaboration, ownership, and meaningful impact. - **Work Model**: Hybrid — full-time contracts in Paris and/or London. - **Engineering & Science Culture**: Multidisciplinary team (Research 41%, Technical 17%) with a flat-ish seniority mix (Specialist 33%, Senior 14%, Manager 13%); talent sourced from top institutions including ENS, Inria, BenevolentAI, Exscientia, and BCG. - **Compensation Benchmarks**: Software Engineer EUR 50,320/year; MLOps Engineer EUR 69,104/year; Intern Software Engineer EUR 15,634/month. - **Open Roles (sample)**: Senior Software Engineer, Staff Software Engineer, Senior Data Engineer, Engineering Manager - Compute Team, AI R&D Manager, Computational Chemist, Drug Discovery Program Leader, Senior People Operations Partner. - **Employer Rating**: 3.4/5 from 21 reviews (Work-Life 3.6, Compensation 3.6, Culture 3.4, Career 3.5). - **Impact**: Direct contribution to inventing new medicines for unsolved diseases, with science moving fast and everyone contributing to the drug discovery pipeline. ## Sources 1. [aqemia.com - Who We Are](https://aqemia.com/who-we-are) 2. [aqemia.com - Careers](https://aqemia.com/careers) 3. [aqemia.com - Pipeline](https://aqemia.com/pipeline) 4. [jobs.lever.co - Aqemia Open Roles](https://jobs.lever.co/aqemia.com) 5. [linkedin.com - Aqemia Company Page](https://linkedin.com/company/aqemia) 6. [welcometothejungle.com - Aqemia](https://www.welcometothejungle.com/fr/companies/aqemia) ## Other roles at Aqemia - [Head of AI](https://feeny.ai/job/head-of-ai-aqemia-paris-f3fe0nq9y791) — Paris, France - [Engineering Manager - Compute Team](https://feeny.ai/job/engineering-manager-compute-team-aqemia-paris-hm22yhpqnj0x) — Paris, France - [Computational Chemist](https://feeny.ai/job/computational-chemist-aqemia-london-8b2pb4kg3nj3) — London, United Kingdom - [Senior People Operations Partner (FR & UK)](https://feeny.ai/job/senior-people-operations-partner-fr-uk-aqemia-paris-svmh9nnvve6a) — Paris, France - [Applied AI Scientist](https://feeny.ai/job/applied-ai-scientist-aqemia-paris-152vfancfhnw) — Paris, France - [Head of Program Lead](https://feeny.ai/job/head-of-program-lead-aqemia-paris-fardfkj3jzw7) — Paris, France - [Drug Discovery Program leader](https://feeny.ai/job/drug-discovery-program-leader-aqemia-paris-ax9eesz4cca8) — Paris, France - [Spontaneous Application](https://feeny.ai/job/spontaneous-application-lithosquare-paris-yx4dnkrg7g46) — Paris, France - [Spontaneous Application](https://feeny.ai/job/spontaneous-application-alta-ares-all-7e7dfjvsewwa) — All - [Spontaneous Application](https://feeny.ai/job/spontaneous-application-in-the-pocket-mcmgq8fhbq9d)